Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.

M, Roffi; DP, Chew; D, Mukherjee; DL, Bhatt; JA, White; C, Heeschen; CW, Hamm; DJ, Moliterno; RM, Califf; HD, White; NS, Kleiman; P, Théroux; EJ, Topol

doi:10.1161/hc4801.100029

Public

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.

Shared by NobleBlocks on Dec 1, 2001 • 12:00 AM UTC

Authors:

Roffi M

Chew DP

Mukherjee D

Abstract

Background Diabetes mellitus is a major risk factor for adverse outcomes after acute coronary syndromes (ACS). Because this disease may be associated with increased platelet aggregation, we investigated whether diabetic patients with ACS derive particular benefit from platelet glycoprotein (GP) IIb/...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!